Study guide
12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot
AMCB Certified Nurse-Midwife CNM
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care
1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral
2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts
2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy
3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy
3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy
4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss
4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care
5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance
5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion
6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation
6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy
7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair
7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture
8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation
8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications
9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage
9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation
10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health
10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis
11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination
11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes
12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days
12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days
13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization
13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening
14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation
14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral
15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders
15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome
16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause
16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis
17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions
17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking
18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity
18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care
12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot
Key Takeaways Explain This Topic AI
The hearing screening benchmark is screen by 1 month, diagnostic evaluation by 3 months, and early intervention enrollment by 6 months.
Automated auditory brainstem response is mandatory for infants in the NICU longer than 5 days because, unlike otoacoustic emissions, it detects auditory neuropathy spectrum disorder.
CCHD screening is performed at 24 hours or later on the right hand and either foot; a pass requires 95 percent or higher in both with a difference of 3 percent or less.
Saturation below 90 percent in either limb is an immediate fail requiring stat echocardiography, while 90 to 94 percent or a difference above 3 percent triggers retesting in 1 hour up to three tests.
The dried blood spot is collected between 24 and 48 hours after at least 24 hours of protein feeding, which is required to detect amino acid disorders such as phenylketonuria.
Last updated: September 2026
- Universal Newborn Screenings
- 1. Universal Newborn Hearing Screening
Hearing impairment is the most common congenital condition, affecting 1 to 3 per 1,000 term infants. Undetected hearing loss leads to severe, irreversible speech, language, and cognitive delays. Screening must be performed prior to hospital discharge under the national "1-3-6" Benchmark :
Screen by 1 month of age .
Comprehensive diagnostic audiological evaluation by 3 months of age for infants who do not pass the initial screen.
Enrollment in multidisciplinary early intervention services by 6 months of age .
Screening Modalities
Otoacoustic Emissions (OAE): A miniature probe in the ear canal emits soft acoustic clicks and measures sound waves generated by the outer hair cells of the cochlea. Quick, non-invasive; however, vernix or fluid in the external ear canal can yield false-positive fails.
Automated Auditory Brainstem Response (AABR): Scalp electrodes measure electrophysiologic neural transmission from the cochlea through the eighth cranial nerve into the brainstem. AABR is mandatory for infants in the NICU >5 days because, unlike OAE, it detects Auditory Neuropathy Spectrum Disorder (ANSD) .
2. Critical Congenital Heart Disease (CCHD) Pulse Oximetry Screening
Critical congenital heart defects (CCHD)—such as hypoplastic left heart syndrome, transposition of the great arteries, tetralogy of Fallot, total anomalous pulmonary venous return, truncus arteriosus, tricuspid atresia, and coarctation of the aorta—depend on ductal patency. When the ductus arteriosus closes post-discharge, these infants suffer catastrophic cardiovascular collapse. CCHD Screening Protocol (Performed at ≥24 hours of life)
- ├── Measure SpO2: RIGHT HAND (Pre-ductal) & EITHER FOOT (Post-ductal)
- ├── PASS: SpO2 ≥95% in BOTH hand & foot AND ≤3% difference between hand and foot
- ├── IMMEDIATE FAIL: SpO2 <90% in EITHER hand or foot ──> Stat Echo & Pediatric Evaluation
- └── RE-TEST (90-94% in either, or >3% difference): Repeat in 1 hr (up to 3 tests total)
Screening Timing: Performed at ≥24 hours of life (to minimize false-positives caused by transitional pulmonary hemodynamics) or immediately prior to discharge if discharged <24 hours.
Sensor Placement: Pulse oximeter sensor placed on the RIGHT HAND (pre-ductal) and EITHER FOOT (post-ductal) .
Algorithmic Interpretation:
PASS: Oxygen saturation is ≥95% in BOTH the right hand and either foot , AND the difference between the right hand and foot is ≤3% . The screen is complete.
IMMEDIATE FAIL: Oxygen saturation is <90% in EITHER the right hand or foot . Requires immediate medical evaluation, supplemental oxygen assessment, and an urgent pediatric echocardiogram.
INDETERMINATE (RE-TEST ZONE): Oxygen saturation is 90% to 94% in either the hand or foot , OR there is a >3% difference between the hand and foot . The infant must be re-tested in 1 hour .
Repeat Testing Protocol: If the second test remains in the indeterminate range, repeat a third time in 1 hour . If the third test still demonstrates 90% to 94% or >3% difference, the screen is classified as a FAIL , requiring an immediate clinical evaluation and pediatric echocardiogram.
3. Dried Blood Spot Metabolic Screening
Collected via capillary heel stick onto specialized filter paper (Guthrie card) between 24 and 48 hours of life , ensuring the infant has ingested protein feedings for at least 24 hours (essential for detecting amino acid disorders). Screened conditions on the Recommended Uniform Screening Panel (RUSP) include:
Phenylketonuria (PKU): Deficiency of phenylalanine hydroxylase. Accumulation of phenylalanine causes profound, irreversible intellectual disability, microcephaly, and seizures. Immediate initiation of a low-phenylalanine medical formula prevents cognitive damage.
Congenital Hypothyroidism: Elevated TSH with decreased free T4. Represents the most common preventable cause of intellectual disability (cretinism). Treatment with oral levothyroxine initiated before 2 weeks of age preserves normal cognitive potential.
Galactosemia: Deficiency of galactose-1-phosphate uridyltransferase (GALT). Ingestion of lactose (glucose + galactose) in breast milk or standard formula causes rapid accumulation of galactose-1-phosphate, resulting in E. coli sepsis , jaundice, cataracts, hepatic cirrhosis, and death. Immediate, permanent transition to soy-based, galactose-free formula is life-saving; breastfeeding is strictly contraindicated .
Sickle Cell Disease & Hemoglobinopathies: Identifies HbSS, HbSC, and beta-thalassemia via isoelectric focusing or HPLC. Initiating daily prophylactic oral penicillin by 2 months of age and pneumococcal vaccination prevents fatal Streptococcus pneumoniae sepsis.
Cystic Fibrosis (CF): Evaluates immunoreactive trypsinogen (IRT), followed by DNA mutation testing for CFTR gene variants.
Congenital Adrenal Hyperplasia (CAH): Most commonly 21-hydroxylase deficiency, leading to elevated 17-hydroxyprogesterone (17-OHP). Causes life-threatening salt-wasting crisis (hyponatremia, hyperkalemia, vascular collapse) in the second week of life, and ambiguous genitalia in genetic females.
Severe Combined Immunodeficiency (SCID): Detected via quantitation of T-cell receptor excision circles (TRECs), identifying severe T-cell lymphopenia before fatal opportunistic infections occur.
Timing, Specimen Quality & Special Populations
The dried blood spot is the screen most often invalidated by process error rather than by biology, and the timing rules are heavily tested:
Collect between 24 and 48 hours of age. Before 24 hours, the metabolites that the panel detects have not had time to accumulate after feeding began, and phenylalanine in particular can still be normal in an affected infant.
If the specimen was unavoidably collected before 24 hours — typically because of an early discharge or transfer — a repeat specimen is required , usually by about 1 to 2 weeks of age.
Transfusion invalidates the screen for hemoglobinopathies and several other analytes, because the transfused donor cells are what get tested. Whenever possible, draw the specimen before transfusing; if not, a repeat is scheduled after the donor cells have cleared.
Preterm, low-birth-weight, and critically ill infants are commonly screened on a repeat schedule, because immature hepatic and endocrine function and parenteral nutrition both distort results.
Specimen quality is the midwife's responsibility. Fill each printed circle completely with a single application of free-flowing blood from one side of the card, do not layer or milk the heel, air-dry horizontally away from heat and direct sunlight, and never place the card in a plastic bag while wet. A layered, clotted, or insufficient spot yields an "unsatisfactory specimen" result and costs days.
Predischarge Bilirubin Assessment
Alongside the three state-mandated screens, current newborn practice includes a universal predischarge bilirubin measurement — transcutaneous or serum — in every infant, plotted on an hour-specific nomogram together with the infant's gestational age and risk factors to determine both the need for treatment and the timing of follow-up. It is not part of the state newborn screening program, but it is universal in practice and is the fourth thing that must be documented before any newborn goes home.
Communicating a Positive Screen
The single most important counseling principle: a screen is not a diagnosis. These panels are deliberately built for high sensitivity, so false positives substantially outnumber true positives, and an out-of-range result means only that confirmatory testing is needed now.
Contact the family promptly and by telephone or in person , never by a message that leaves them to interpret it alone.
State plainly that the screen was out of range, that most out-of-range screens turn out to be normal on confirmatory testing, and that the next step is a specific test on a specific date.
Arrange the confirmatory test and the specialist referral before ending the conversation, and document who is responsible for the result.
Out-of-hospital births carry the same obligations. The midwife who attends a home or birth-center birth owns the hearing screen, the pulse oximetry screen, the blood spot, and the bilirubin check — including tracking the results to closure.